Stonebrook Private Inc. Has $709,000 Stock Holdings in STERIS plc (NYSE:STE)

Stonebrook Private Inc. increased its stake in STERIS plc (NYSE:STE) by 9.9% during the second quarter, Holdings Channel.com reports. The fund owned 3,230 shares of the medical equipment provider’s stock after buying an additional 290 shares during the period. Stonebrook Private Inc.’s holdings in STERIS were worth $709,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. First Personal Financial Services bought a new stake in shares of STERIS in the 1st quarter valued at $25,000. J.Safra Asset Management Corp raised its position in shares of STERIS by 77.9% in the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 53 shares in the last quarter. Quent Capital LLC raised its position in shares of STERIS by 112.7% in the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 71 shares in the last quarter. VisionPoint Advisory Group LLC acquired a new position in shares of STERIS in the 4th quarter valued at about $34,000. Finally, Headlands Technologies LLC bought a new stake in shares of STERIS during the 1st quarter valued at about $36,000. 94.69% of the stock is currently owned by institutional investors.

STERIS Stock Up 0.3 %

Shares of STE stock traded up $0.77 on Friday, hitting $239.82. The stock had a trading volume of 365,096 shares, compared to its average volume of 351,923. STERIS plc has a 12-month low of $195.47 and a 12-month high of $245.81. The stock has a market cap of $23.65 billion, a price-to-earnings ratio of 62.78 and a beta of 0.83. The business has a 50 day moving average of $230.92 and a 200 day moving average of $224.83. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49.

STERIS (NYSE:STE) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $1.98 by $0.16. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter last year, the firm earned $2.00 EPS. The company’s quarterly revenue was down .4% compared to the same quarter last year. As a group, analysts expect that STERIS plc will post 9.05 EPS for the current year.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Investors of record on Thursday, September 5th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend is Thursday, September 5th. This is a boost from STERIS’s previous quarterly dividend of $0.52. STERIS’s payout ratio is 54.45%.

Insider Activity

In other STERIS news, Director Christopher S. Holland sold 473 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at $139,493.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on STE shares. Piper Sandler reissued a “neutral” rating and issued a $225.00 price target (up from $220.00) on shares of STERIS in a research note on Friday, May 10th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a research note on Tuesday, August 13th. JMP Securities reissued a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. Finally, KeyCorp upped their target price on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and a consensus target price of $246.00.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.